Search results for " Myocardial"

showing 10 items of 305 documents

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease

2021

Platelets are the main players in thrombotic diseases, where activated platelets not only mediate thrombus formation but also are involved in multiple interactions with vascular cells, inflammatory components, and the coagulation system. Although in vitro reactivity of platelets provides information on the function of circulating platelets, it is not a full reflection of the in vivo activation state, which may be relevant for thrombotic risk assessment in various disease conditions. Therefore, studying release markers of activated platelets in plasma is of interest. While this type of study has been done for decades, there are several new discoveries that highlight the need for a critical a…

0301 basic medicineACUTE MYOCARDIAL-INFARCTIONVON-WILLEBRAND-FACTORDEEP VENOUS THROMBOSISvenous thromboembolismCD40 LIGANDContext (language use)ReviewDiseaseCardiovascular Medicinearterial thrombosis030204 cardiovascular system & hematologyBioinformatics03 medical and health sciences0302 clinical medicineVon Willebrand factorPERIPHERAL ARTERY-DISEASENONVALVULAR ATRIAL-FIBRILLATIONmedicineDiseases of the circulatory (Cardiovascular) systematrial fibrillationPlateletACUTE ISCHEMIC-STROKEMyocardial infarctionPlatelet activationThrombusthrombosisbiologybusiness.industryACUTE CORONARY SYNDROMESbiomarkersmedicine.diseaseThrombosisC-REACTIVE PROTEIN3. Good healthP-SELECTIN LEVELS030104 developmental biologyRC666-701plateletsbiology.proteinCardiology and Cardiovascular MedicinebusinessFrontiers in Cardiovascular Medicine
researchProduct

Cardiac troponin elevation in patients with influenza virus infections

2021

The association between acute infections and cardiac injury, including myocarditis and acute myocardial infarction, is now well established. We have performed a systematic literature review for analyzing the results of epidemiological studies that measured cardiac troponins (cTn) in patients with Influenza virus infections. Overall, 14 articles were finally identified and analyzed. Taken together, the results of the scientific literature suggest that cTn elevation is a relatively rare phenomenon in patients with Influenza virus infection, with frequency generally comprised between 0 and 33%, more likely in elderly patients with significant comorbidities. In patients with modest cTn elevatio…

0301 basic medicineAdultMalemedicine.medical_specialtyMedicine (General)MyocarditisCardiac troponinAdolescentQH301-705.5Myocardial InfarctionDiseaseInfluenza A Virus H7N9 SubtypeVirus03 medical and health sciencesYoung Adult0302 clinical medicineInfluenza A Virus H1N1 SubtypeR5-920Internal medicineEpidemiologyInfluenza HumanMedicineHumansMyocardial infarctionBiology (General)health care economics and organizationsAgedAged 80 and overbusiness.industryCardiac injury Cardiac troponin Influenza Myocardial injuryGeneral MedicineMiddle Agedmedicine.diseaseShort ReviewTroponinInfluenzaCardiac injury030104 developmental biology030220 oncology & carcinogenesisConcomitantMyocardial injuryBiomarker (medicine)Cardiac troponinFemalebusinessBiomarkers
researchProduct

Disparate miRNA expression in serum and plasma of patients with acute myocardial infarction: a systematic and paired comparative analysis

2020

AbstractDespite the promising value of miRNAs in the diagnostic and prognostic of cardiovascular disease (CVD), recent meta-analyses did not support their potential. Methodological variances in studies may interfere with miRNA profile and affect their results. This study determines if the blood starting material is a source of variance in miRNA profile by performing a paired comparison in plasma and serum of the expression of primary miRNAs associated with CVD. Circulating miRNA yield was similar in both plasma and serum, although a significant increase was observed in patients with Non-ST-elevation myocardial infarction (NSTEMI) compared to control volunteers. When normalized by the expres…

0301 basic medicineCirculating mirnasMaleMicro RNAsMyocardial InfarctionOld agelcsh:MedicineGene Expression030204 cardiovascular system & hematologyBlood plasmaPlasma0302 clinical medicineMyocardial infarctionlcsh:ScienceNon-ST Elevated Myocardial InfarctionMultidisciplinaryMiddle AgedPrognosisVellesamiRNAsFemalemedicine.medical_specialtyPaired comparisonFisiologiaPredictive markersArticle03 medical and health sciencesMirna expressionInternal medicinemicroRNAmedicineHumansIn patientCorCirculating MicroRNAAgedbusiness.industrylcsh:RPlasma sanguinimedicine.diseaseInfart de miocardiMicroRNAsMyocardial infarction030104 developmental biologyEndocrinologyROC Curvelcsh:QbusinessTranscriptomeBiomarkers
researchProduct

Microparticles harbouring Sonic hedgehog morphogen improve the vasculogenesis capacity of endothelial progenitor cells derived from myocardial infarc…

2019

Aims Endothelial progenitor cells (EPC) play a role in endothelium integrity maintenance and regeneration. Decreased numbers of EPC or their impaired function correlates with an increase in cardiovascular events. Thus, EPC are important predictors of cardiovascular mortality and morbidity. Microparticles carrying Sonic hedgehog (Shh) morphogen (MPShh+) trigger pro-angiogenic responses, both in endothelial cells and in ischaemic rodent models. Here, we propose that MPShh+ regulates EPC function, thus enhancing vasculogenesis, and correcting the defects in dysfunctional EPC obtained from acute myocardial infarction (AMI) patients. Methods and results The mechanisms underlying Shh pathway func…

0301 basic medicineEndotheliumNitric Oxide Synthase Type IIIPhysiologyAngiogenesis[SDV]Life Sciences [q-bio]Myocardial InfarctionMice NudeNeovascularization PhysiologicAcute myocardial infarction030204 cardiovascular system & hematologyMicroparticlesZinc Finger Protein GLI103 medical and health sciences0302 clinical medicineVasculogenesisCell-Derived MicroparticlesPhysiology (medical)Paracrine CommunicationVasculogenesismedicineAnimalsHumansHedgehog ProteinsProgenitor cellSonic hedgehogAngiogenic ProteinsCells CulturedComputingMilieux_MISCELLANEOUSEndothelial progenitor cellsbiologybusiness.industryNitric oxideSmoothened ReceptorHedgehog signaling pathwayPatched-1 ReceptorVascular endothelial growth factor A030104 developmental biologymedicine.anatomical_structureCase-Control StudiesKLF2embryonic structuresCancer researchbiology.proteincardiovascular systemCardiology and Cardiovascular MedicinebusinessSignal Transductioncirculatory and respiratory physiology
researchProduct

Plasma phospholipid transfer protein (PLTP) modulates adaptive immune functions through alternation of T helper cell polarization

2016

International audience; Objective: Plasma phospholipid transfer protein (PLTP) is a key determinant of lipoprotein metabolism, and both animal and human studies converge to indicate that PLTP promotes atherogenesis and its thromboembolic complications. Moreover, it has recently been reported that PLTP modulates inflammation and immune responses. Although earlier studies from our group demonstrated that PLTP can modify macrophage activation, the implication of PLTP in the modulation of T-cell-mediated immune responses has never been investigated and was therefore addressed in the present study. Approach and results: In the present study, we demonstrated that PLTP deficiency in mice has a pro…

0301 basic medicineLymphocyteIpid Transfer ProteinAdaptive ImmunityCardiovascular-DiseaseT-Lymphocytes RegulatoryLipoprotein MetabolismLeukocyte CountPhospholipid transfer proteinPolarizationImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyHypersensitivity DelayedPhospholipid Transfer ProteinsCell PolarityCell DifferentiationT-Lymphocytes Helper-InducerT helper cellFlow CytometryAcquired immune systemCell biologyInfectious Diseasesmedicine.anatomical_structureEndothelial-CellsCytokines[SDV.IMM]Life Sciences [q-bio]/ImmunologyLymphocytemedicine.symptomResearch ArticleDensity-Lipoprotein[SDV.IMM] Life Sciences [q-bio]/ImmunologyHuman Atherosclerotic PlaquesT cellCirculating Interleukin-18ImmunologyT CellAntigen-Presenting CellsInflammationAcute Myocardial-InfarctionGATA3 Transcription FactorBiology03 medical and health sciencesImmune systemmedicineAnimalsAntigen-presenting cellDeficient MiceAlpha-TocopherolMice Inbred C57BL030104 developmental biologyImmunologyVitamin-ET-Box Domain ProteinsBiomarkersSpleen
researchProduct

Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome

2019

Objectives The endocannabinoid system modulates coronary circulatory function and atherogenesis. The two major endocannabinoids (eCB), 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide (AEA), are increased in venous blood from patients with coronary artery disease (CAD). However, given their short half-life and their autocrine/paracrine mechanism of action, eCB levels in venous blood samples might not reflect arterial or coronary eCB concentrations. The aim of this cross-sectional study was to identify the local concentration profile of eCB and to detect whether and how this concentration profile changes in CAD and NSTEMI versus patients without CAD. Methods and results 83 patien…

0301 basic medicineMalePhysiologyMyocardial InfarctionCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyVascular MedicineBiochemistryCoronary artery disease0302 clinical medicineMedicine and Health SciencesMedicineCoronary Heart DiseaseMyocardial infarctionNon-ST Elevated Myocardial InfarctionCoronary ArteriesAortaAged 80 and overMultidisciplinaryArachidonic AcidQREukaryotaNeurochemistryVenous bloodArteriesPlantsMiddle AgedLegumesLipidsCoronary VesselsBody Fluidsmedicine.anatomical_structureBloodCirculatory systemCardiologyMedicineArterial bloodEngineering and TechnologyFemaleAnatomyNeurochemicalsResearch ArticleBiotechnologyAcute coronary syndromemedicine.medical_specialtyCathetersScienceCardiologyBioengineeringArachidonic AcidsGlyceridesDiagnosis Differential03 medical and health sciencesCoronary circulationInternal medicineCoronary CirculationHumansAcute Coronary SyndromeAgedbusiness.industryMacrophagesOrganismsPeasBiology and Life Sciencesmedicine.diseaseCoronary arteries030104 developmental biologyCross-Sectional StudiesCardiovascular AnatomyBlood VesselsMedical Devices and EquipmentEndothelium VascularbusinessEndocannabinoidsNeurosciencePLoS ONE
researchProduct

Relation between high levels of myeloperoxidase in the culprit artery and microvascular obstruction, infarct size and reverse remodeling in ST-elevat…

2017

International audience; MAIN OBJECTIVE: To better understand the role of myeloperoxidases (MPO) in microvascular obstruction (MO) phenomenon and infarct size (IS) using cardiac magnetic resonance (CMR) data in patients with acute myocardial infarction (AMI).METHOD: 40 consecutive patients classified according to the median level of MPO in the culprit artery. A CMR study was performed during the week following AMI and at 6 months, with late gadolinium enhancement sequences.RESULTS: Persistent MO was observed in the same proportion (50 vs. 65%, p = 0.728) between the low vs. high MPO group levels. However, the extent of the microvascular obstruction was significantly greater in the high-MPO g…

0301 basic medicineMalePhysiologyNeutrophilsMyocardial Infarctionlcsh:Medicine030204 cardiovascular system & hematologyBiochemistryVentricular Function Leftchemistry.chemical_compoundWhite Blood CellsOxidative Damage0302 clinical medicineAnimal CellsMedicine and Health SciencesDiseaseMyocardial infarction[ SDV.IB ] Life Sciences [q-bio]/Bioengineeringlcsh:ScienceMultidisciplinaryEjection fractionbiologyVentricular RemodelingNeurochemistryStroke volumeArteriesMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPathophysiologyBody FluidsBloodMyeloperoxidaseCreatinineCardiologyFemale[SDV.IB]Life Sciences [q-bio]/BioengineeringAnatomyNeurochemicalsCellular TypesResearch Articlemedicine.medical_specialtyImmune CellsImmunologyCardiologyMagnetic Resonance Imaging CineNitric OxideLong-TermBlood PlasmaNo-Reflow03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineDimethylargininemedicineHumanscardiovascular diseasesMortalityVentricular remodelingAgedPeroxidaseCreatinineBlood Cellsbusiness.industryMicrocirculationlcsh:RBiology and Life SciencesStroke VolumeCell BiologyDefinitionLeukocytemedicine.diseaseTroponin030104 developmental biologychemistrybiology.proteinCardiovascular AnatomyBlood VesselsST Elevation Myocardial Infarctionlcsh:QbusinessReactive Oxygen SpeciesAcute Coronary SyndromesBiomarkersNeuroscienceEjection Fraction
researchProduct

Computational modeling of bicuspid aortopathy: Towards personalized risk strategies.

2019

This paper describes current advances on the application of in-silico for the understanding of bicuspid aortopathy and future perspectives of this technology on routine clinical care. This includes the impact that artificial intelligence can provide to develop computer-based clinical decision support system and that wearable sensors can offer to remotely monitor high-risk bicuspid aortic valve (BAV) patients. First, we discussed the benefit of computational modeling by providing tangible examples of in-silico software products based on computational fluid-dynamic (CFD) and finite-element method (FEM) that are currently transforming the way we diagnose and treat cardiovascular diseases. Then…

0301 basic medicineProcess (engineering)Computer scienceFinite Element AnalysisHeart Valve DiseasesWearable computerCoronary Artery Disease030204 cardiovascular system & hematologyClinical decision support system03 medical and health sciences0302 clinical medicineSoftwareBicuspid aortic valveBicuspid Aortic Valve DiseaseArtificial IntelligencemedicineHumansClinical careMolecular Biologybusiness.industryHemodynamicsModels Cardiovascularaortic failure bicuspid aortic valvemedicine.diseaseFractional Flow Reserve Myocardial030104 developmental biologyRisk analysis (engineering)Aortic ValvePersonalized medicineCardiology and Cardiovascular MedicinebusinessJournal of molecular and cellular cardiology
researchProduct

Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublis…

2018

Zofenopril is a lipophilic, sulfhydryl group-containing angiotensin-converting enzyme (ACE)-inhibitor, characterized by wide tissue distribution, long duration of action, and pleiotropic effects on endothelial dysfunction. Its clinical efficacy and safety have been described in the four randomized controlled trials of the SMILE program, which globally enrolled more than 3600 patients in post-acute myocardial infarction (AMI) setting. The SMILE-4 study specifically selected patients with left ventricular dysfunction at admission, and compared the effects of zofenopril or ramipril in combination with acetylsalicylic acid (ASA). Zofenopril demonstrated its superiority over ramipril in reducing…

0301 basic medicineRamiprilmedicine.medical_specialtyCaptoprilPopulationMyocardial InfarctionCardiologyAngiotensin-Converting Enzyme InhibitorsHeart failureReviewAcute myocardial infarction030204 cardiovascular system & hematologylaw.inventionZofenopril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineAcute myocardial infarction; Angiotensin-converting enzyme inhibitors; Cardiology; Heart failure; Left ventricular dysfunction; Ramipril; Zofenopril; Pharmacology (medical)MedicineHumansPharmacology (medical)Myocardial infarctioneducationRandomized Controlled Trials as Topiceducation.field_of_studyLeft ventricular dysfunctionEjection fractionbusiness.industryGeneral Medicinemedicine.diseaseZofenopril030104 developmental biologyTreatment OutcomechemistryAngiotensin-converting enzyme inhibitorHeart failureCardiologyNumber needed to treatbusinessmedicine.drug
researchProduct